Search Results

% to 30% marrow blasts (azacitidine, decitabine) and for other indications (clofarabine, lenalidomide), those denied approval based on testing but that are still under evaluation (tipifarnib), and those still in early testing (sapacitabine). The novel

or follicular helper T-cell lymphomas. 9 There were responses in some rare T-cell lymphomas, such as gamma-delta T-cell lymphomas, but no responses in patients with PTCL-NOS. Finally, tipifarnib, a farnesyltransferase inhibitor, has been shown to

[abstract] . Blood 2007 ; 110 : Abstract 818 . 27. Lancet JE Gojo I Gotlib J . A phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia . Blood

mitogen-activated protein kinase pathway (e.g., tipifarnib), the second generation proteosome inhibitor carfilzomib, the immunomodulator pomalidomide, and histone deacetylase inhibitors such as belinostat and panobinostat. Many of the issues will be

[abstract] . Blood 2005 ; 106 : Abstract 404 . 79. Lancet JE Gojo I Gotlib J . A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia . Blood

Karasek P . Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer . J Clin Oncol 2004 ; 22 : 1430 – 1438 . 39 Mendelsohn J Baselga J . Status of epidermal growth factor receptor

patients older than 50 years of age . Blood 2005 ; 105 : 1810 – 1814 . 50. Lancet J Gotlib J Gojo I . Tipifarnib (ZARNESTRATM in previously untreated poor-risk aml of the elderly: updated results of a multicenter Phase 2 trial . Blood 2004

cells from patients with chronic myeloid leukemia . Blood 2001 ; 97 : 1404 – 1412 . 61 Gotlib J Mauro MJ O'Dwyer ME . Tipifarnib (ZARNESTRA) and imatinib (GLEEVEC) combination therapy in patients with advanced chronic myelogenous leukemia

9924) study . Invest New Drugs 2005 ; 23 : 485 – 487 . 25. Van Cutsem E van de Velde H Karasek P . Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer . J Clin Oncol 2004

. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma . Blood 2004 ; 103 : 3271 – 3277 . 112. Nguyen AN